Vigil NeuroscienceVIGL
VIGL
About: Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
Employees: 66
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.33% more ownership
Funds ownership: 69.59% [Q2] → 69.92% (+0.33%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
10% less capital invested
Capital invested by funds: $105M [Q2] → $94.5M (-$10.2M) [Q3]
10% less funds holding
Funds holding: 58 [Q2] → 52 (-6) [Q3]
33% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 18
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
900%
upside
Avg. target
$21
1,135%
upside
High target
$24
1,312%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Jason Butler 33% 1-year accuracy 13 / 40 met price target | 1,194%upside $22 | Market Outperform Reiterated | 26 Nov 2024 |
Wedbush Laura Chico 32% 1-year accuracy 20 / 62 met price target | 1,312%upside $24 | Outperform Maintained | 8 Nov 2024 |
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target | 900%upside $17 | Buy Reiterated | 8 Nov 2024 |
Financial journalist opinion
Neutral
PRNewsWire
2 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
Neutral
GlobeNewsWire
3 months ago
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927. The FDA's decision was based on a complete response submitted by the Company.
Neutral
GlobeNewsWire
3 months ago
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET.
Neutral
GlobeNewsWire
3 months ago
Vigil Neuroscience to Present at Upcoming September Investor Conferences
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences.
Neutral
PRNewsWire
3 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
Neutral
GlobeNewsWire
4 months ago
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - - Announced interim data from VG-3927 Phase 1 trial in healthy volunteers that support continued development as potential therapy for Alzheimer's disease - WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2024, and provided an update on recent progress.
Neutral
GlobeNewsWire
4 months ago
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease
- Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for Alzheimer's disease (AD) -
Neutral
GlobeNewsWire
5 months ago
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations highlighting its oral small molecule VG-3927 at the 2024 Alzheimer's Association International Conference (AAIC) taking place on July 28-August 1, 2024 in Philadelphia, Pennsylvania and virtually.
Neutral
GlobeNewsWire
5 months ago
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today an update following a Type C Meeting with the U.S. Food and Drug Administration (FDA) to its clinical development strategy for its IGNITE clinical trial evaluating iluzanebart in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
Neutral
PRNewsWire
5 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
NEW YORK , July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
Charts implemented using Lightweight Charts™